China is using artificial intelligence to accelerate drug discovery and develop new therapies as part of a large-scale pharmaceutical boom.

This shift represents a strategic effort to increase innovation efficiency and position China as a global leader in next-generation medical breakthroughs. By reducing the time and cost associated with traditional drug development, the country aims to redefine the future of medicine through high-tech integration.

Cross-border AI-driven drug deals in China reached US$110 billion [1] in the first half of 2026. This surge in investment reflects a growing appetite for AI-powered candidates to drive the next wave of pharmaceutical deals [1]. The broader AI pharma market in China is similarly projected at $110 billion [2].

The initiative involves a mix of government agencies and private pharmaceutical companies. These entities are increasingly partnering with international firms to replenish their research pipelines. One such collaboration includes the U.S.-based Bristol Myers Squibb and China's Hengrui Pharma [3].

These technological advancements have already yielded significant results on a global scale. China now develops about 30% [1] of new therapies worldwide. The integration of AI allows researchers to identify viable drug candidates more quickly than traditional methods, a process that has historically taken years of trial and error.

Collaborations now extend beyond domestic borders, linking Chinese laboratories with research hubs in the U.S. and Europe [3]. This network of cooperation is designed to speed up the delivery of medicines to patients while securing China's role in the global healthcare supply chain [2].

“Cross-border AI-driven drug deals in China reached US$110 billion in the first half of 2026.”

The scale of investment in AI-driven pharmacology suggests a pivot from traditional chemical synthesis to data-driven discovery. By capturing nearly a third of new global therapies, China is utilizing AI to bypass traditional development bottlenecks, potentially shifting the center of pharmaceutical innovation away from Western hubs and toward a more integrated, AI-centric global model.